Future Oncology · 2017 · 27 citations · 11 references
MedicineCancer BiologyOncologyEpigeneticsEpigenomicsMolecular OncologyCancer EpigeneticsCancer EpigenomicsCancer GenomicsMalignant NeoplasmsMolecular Tumor ProfilingPancreatic CancerAberrant Dna MethylationBiomarker DetectionCancer Dna Methylation SignaturesCancer Epigenetic BiomarkersCancer Epigenome MappingCancer Genomic Biomarker DiscoveryMethylation ReactionsPrognostic Prediction
AIM: We explore the biomarker potential of the TERT hypermethylated oncologic region (THOR) in pancreatic cancer. MATERIALS & METHODS: We assessed the methylation status of THOR using the cancer genome atlas data on the cohort of pancreatic cancer (n = 193 patients). RESULTS: THOR was significantly hypermethylated in pancreatic tumor tissue when compared with the normal tissue used as control (p < 0.0001). Also, THOR hypermethylation could distinguish early stage I disease from normal tissue and was associated with worse prognosis. DISCUSSION: We found that THOR is hypermethylated in pancreatic tumor tissue when compared with normal tissue and that THOR methylation correlates with TERT expression in tumor samples. CONCLUSION: Our preliminary findings support the diagnostic and prognostic values of THOR in pancreatic cancer.
11
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.2K citations · Full text
Highly Recurrent <i>TERT</i> Promoter Mutations in Human Melanoma
Franklin W. Huang, Eran Hodis, Mary Jue Xu et al. · Science · 2013 · 1.8K citations · Full text